Ligand-binding domain of estrogen receptors

Current Opinion in Biotechnology

Volumn 10, Issue 6, 1999, Pages 550-556

  Mueller Fahrnow, Anke ^a   Egner, Ursula ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; LIGAND; MUTANT PROTEIN; RECEPTOR SUBTYPE; REPRESSOR PROTEIN;

AMINO ACID SEQUENCE; BINDING SITE; CONFORMATIONAL TRANSITION; DIMERIZATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 0032728389     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00034-8     Document Type: Review

References (50)

1. Katzenellenbogen B.S. Estrogen receptors: bioactivities and interaction with cell signaling pathways. Biol Reprod. 54:1996;287-293.
2. Ciocca D.R., Roig L.M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocrinol Rev. 16:1995;35-62.
3. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol. 10:1998;384-391. The authors give an overview of different nuclear receptor ligand-binding domains structures in a condensed form. The most relevant information on co-activators/co-repressors is also presented.
4. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engström O., Öhman L., Green G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
5. Tannenbaum D.M., Wang Y., Williams S.P., Sigler P.B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA. 95:1998;5998-6003.
6. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937. The first example of a crystal structure of a ternary complex of the hERα ligand-binding domain (LBD) in complex with an agonist (diethylstilbestrol) and a co-activator fragment. The crystal structure of the hER LBD in complex with a partial agonist, tamoxifen, is also presented. The structural basis for co-activator recognition is also discussed with respect to the interaction of tamoxifen with the protein.
7. Pike A.C.W., Brzozowski A.M., Hubbard R.E., Bonn I., Thorsell A.G., Engström O., Ljunggren J., Gunstafsson J.A., Corlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full agonist. EMBO J. 18:1999;4608-4618.
8. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 375:1995;377-382.
9. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
10. Wagner R.L., Apriletti J.W., McGrath M.E., West B.L., Baxter J.D., Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature. 378:1995;690-697.
11. Ribeiro R.C.J., Apriletti J.W., Wagner R.L., Feng W., Kushner P.J., Nilsson S., Scanlan T.S., West B.L., Fletterick R.J., Baxter J.D. X-ray crystallographic and functional studies of thyroid hormone receptor. J Steroid Biochem Molec Biol. 65:1998;133-141.
12. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature. 393:1998;392-396.
13. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ Nature. 395:1998;137-143.
14. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ J Biol Chem. 273:1998;31108-31112.
15. Klaholz B.P., Renaud J.P., Mitschler A., Zusi C., Chambon P., Gronemeyer H., Moras D. Conformational adaption of agonists to the human nuclear receptor RARγ Nat Struct Biol. 5:1998;199-202.
16. Kuiper G.G.J.M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:1996;5925-5930.
17. Giguere V., Yang N., Segui P., Evans R.M. Identification of a new class of steroid hormone receptors. Nature. 331:1988;91-94.
18. Saunders P. Oestrogen receptor beta (ERβ). Rev Reprod. 3:1998;164-171.
19. Moore J.T., McKee D.D., Slentz-Kesler K., Moore L.B., Jones S.A., Horne E.L., Su J.L., Kliewer S.A., Lehmann J.M., Willson T.M. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun. 247:1998;75-78.
20. Vladusik E.A., Hornby A.E., Guerra Vladusik F.K., Lupu R. Espression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res. 58:1998;210-214.
21. Petersen D.N., Tkalcevic G.T., Koza-Taylor P.H., Turi T.G., Brown T.A. Identification of estrogen receptor β2, a functional variant of estrogen receptor β expressed in normal rat tissues. Endocrinology. 139:1998;1082-1092.
22. Maruyama K., Endoh H., Sasaki-Iwaoka H., Kanou H., Shimaya E., Hashimoto S., Kato S., Kawashima H.A. novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regulator of estrogen action. Biochem Biophys Res Commun. 246:1998;142-147.
23. Murphy L.C., Dotzlaw H., Leygue E., Douglas D., Coutts A., Watson P.H. Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol. 62:1997;363-372.
24. Bairoch A., Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999. Nucleic Acid Res. 27:1999;49-54.
25. Anstead G.M., Carlson K.E., Katzenellenbogen J.A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids. 62:1997;268-303.
26. Wurtz J.M., Egner U., Heinrich N., Moras D., Mueller-Fahrnow A. Three dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationship data. J Med Chem. 11:1998;1803-1814. Thorough comparative modelling study. The hERα ligand-binding domain (LBD) model is evaluated based on the analysis of ligands and their relative binding affinities. The article provides a list of mutants within the LBD of human and mouse estrogen receptor evaluating the binding affinities with respect to the wild-type receptor.
27. Kuiper G.G.J.M., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β Endocrinology. 139:1998;4252-4263.
28. Grese T.A., Dodge J.A. Selective estrogen receptor modulators (SERMs). Curr Pharmaceut Des. 4:1998;71-92.
29. Levenson A.S., Jordan V.C. The key to antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1998;1872-1875.
30. Macgregor J.I., Jordan V.C. Basic guide to the mechanism of antiestrogen action. Pharmacol Rev. 50:1998;151-196.
31. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β Endocrinology. 140:1999;800-804.
32. Gao H., Katzenellenbogen J.A., Garg R., Hansch C. Comparative QSAR analysis of estrogen receptor ligands. Chem Rev. 99:1999;723-744. This study provides detailed information on comparative structure-activity relationships of steroidal and non-steroidal estrogen receptor ligands. Factors influencing the relative binding affinity, for example, the steric and polar character of substituents are highlighted. The quality of the derived relationships is critically analysed.
33. Huang N., von Baur E., Garnier J.M., Lerouge T., Vonesch J.L., Lutz Y., Chambon P., Losson R. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J. 17:1998;3398-3412.
34. vom Baur E., Harbers M., Um S.J., Benecke A., Chambon P., Losson R. The yeast Ada complex mediates the ligand-dependent activation function AF-2 of retinoid X and estrogen receptors. Genes Dev. 12:1998;1278-1289.
35. Johansson L., Thomsen J.S., Damdimopoulos A.E., Spyrou G., Gustafsson J.A., Treuter E. The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activation of estrogen receptors ERα and ERβ J Biol Chem. 274:1999;345-353.
36. Norris J.D., Fan D., Stallcup M.R., McDonnell D.P. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem. 273:1998;6679-6688. The authors analyze the interaction of the co-activator GRIP1 with the estrogen receptor. They suggest that GRIP1 may not only interact with the transactivation function 2 (AF-2) of the ligand-binding domain (LBD) but also contacts the receptor in yet unidentified areas of the LBD. The results are supported by mutagenesis experiments of selected amino acid residues in helix H12 of the LBD.
37. Peters G.A., Khan S.A. Estrogen receptor domains E and F: role in dimerisation and interaction with coactivator RIP-140. Mol Endocrinol. 13:1999;286-296.
38. Parker M.G. Transcriptional activation by oestrogen receptors. Biochem Soc Symp. 63:1998;45-50.
39. Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 11:1997;657-666.
40. Smith E.P., Boyd J., Frank G., Takahashi H., Cohen R., Specker B., Williams T., Lubahn D., Korach K. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med. 331:1994;1056-1061.
41. Umekita Y., Sagara Y., Yoshida H. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res. 89:1998;27-32.
42. Nichols M., Rientjes J.M.J., Stewart A.F. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J. 17:1998;765-773.
43. Ekena K., Katzenellenbogen J.A., Katzenellenbogen B.S. Determinants of ligand binding specificity of estrogen receptor-α: estrogen versus androgen discrimination. J Biol Chem. 273:1998;693-699.
44. Tremblay G.B., Tremblay A., Labrie F., Giguère V. Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res. 58:1998;877-881.
45. Tremblay G.B., Tremblay A., Labrie F., Giguère V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and-2 in the estrogen receptor α-β heterodimeric complex. Mol Cell Biol. 19:1999;1919-1927.
46. Feng W., Ribeiro R.C.J., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
47. Taylor J.A., Lewis K.J., Lubahn D.B. Estrogen receptor mutations. Mol Cell Endocrinol. 145:1998;61-66.
48. Miller N., Whelan J. Random mutagenesis of human estrogen receptor ligand binding domain identifies mutations that decrease sensitivity to estradiol and increase sensitivity to a diphenol indene-ol compound: basis for a regulatable expression system. J Steroid Biochem Mol Biol. 64:1998;129-135.
49. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acid Res. 22:1994;4673-4680.
50. Insight98.0. San Diego, USA: MSI Inc.; 1998.